Parmar Vinendra
1Ph. D scholar, Department of pharmacology, L. M. College of pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India. E mail: vinendra_15890@yahoo.com 2Associate Professor, Department of pharmacology, L. M. College of pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India. Objectives: The purpose of this study was to investigate the efficacy and safety of teneligliptin, a completely unique and highly selective DPP-4 inhibitor in type 2 diabetes mellitus (T2DM) patients having dyslipidemia who are inadequately controlled by relevant conventional therapy in India. Methods: Study protocol was approved by Institutional Ethics Committee. Diabetic patients having dyslipidemia (male/female) were randomized to receive treatments in two groups, namely conventional therapy [treatment (A)] and add on teneligliptin 20 mg with conventional therapy [treatment (B)] for 24 weeks. Predesigned case report form (CRF) was used to collect information from the prescribing physicians regarding the efficacy and safety of teneligliptin. Efficacy variables included change in serum glycaemic, lipid, and cytokines (IL-6, TNF-α and adiponectin) levels from baseline to week 24. Treatmentemergent adverse events (TEAEs) were also assessed.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu